COYA trades 118.2% below Wall Street's consensus target of $12.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes COYA achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 5 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 29, 2026, Coya Therapeutics, Inc. (COYA) has a Wall Street consensus price target of $12.00, based on estimates from 5 covering analysts. With the stock currently trading at $5.50, this represents a potential upside of +118.2%. The company has a market capitalization of $100M.
Analyst price targets range from a low of $12.00 to a high of $12.00, representing a 0% spread in expectations. The median target of $12.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 5 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, COYA trades at a trailing P/E of -4.3x. Analysts expect EPS to grow -7.5% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
NRXPNRx Pharmaceuticals, Inc. | $64M | $3.73 | — | — | — | — | — |
INMBINmune Bio, Inc. | $38M | $1.42 | — | — | — | — | — |
PRAXPraxis Precision Medicines, Inc. | $9.5B | $327.79 | $584.00 | +78.2% | Buy | — | 16 |
ACIUAC Immune S.A. | $261M | $2.56 | $7.00 | +173.4% | Buy | — | 9 |
SAVACassava Sciences, Inc. | $64M | $1.32 | — | — | Buy | — | 12 |
ANVSAnnovis Bio, Inc. | $34M | $1.72 | — | — | — | — | — |
ATHAAthira Pharma, Inc. | $17M | $4.34 | — | — | — | — | — |
NKTRNektar Therapeutics | $1.2B | $63.65 | $149.60 | +135.0% | Buy | — | 33 |
BIIBBiogen Inc. | $31.9B | $216.03 | $218.32 | +1.1% | Buy | 14.9x | 48 |
LLYEli Lilly and Company | $1.1T | $1206.51 | $1269.94 | +5.3% | Buy | 33.0x | 45 |
Quick answers to the most common questions about buying COYA stock.
The consensus Wall Street price target for COYA is $12, representing 118.2% upside from the current price of $5.5. With 5 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
COYA has a consensus rating of "Buy" based on 5 Wall Street analysts. The rating breakdown is predominantly bullish, with 5 Buy/Strong Buy ratings. The consensus 12-month price target of $12 implies 118.2% upside from current levels.
COYA's current price is $5.5 with a consensus target of $12 (118.2% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $12 for COYA, while the most conservative target is $12. The consensus of $12 represents the median expectation. These targets typically reflect 12-month expectations.
COYA is moderately covered, with 5 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 5 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month COYA stock forecast based on 5 Wall Street analysts shows a consensus price target of $12, with estimates ranging from $12 (bear case) to $12 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on COYA, with a "Buy" consensus rating and $12 price target (118.2% upside). 5 of 5 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
COYA analyst price targets range from $12 to $12, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $12 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.